Protagonist Therapeutics (PTGX) IPO Opened Flat

Today's IPO for Protagonist Therapeutics (NASDAQ: PTGX) opened for trading earlier at $12 after pricing 7,500,000 shares of common stock at a price to the public of $12 per share, the middle of the expected $11 - $13 range.

Leerink Partners LLC, Barclays Capital Inc. and BMO Capital Markets Corp. are acting as joint book-running managers for the offering.

Protagonist Therapeutics is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities to address significant unmet medical needs.

You May Also Be Interested In

• CopperTech Metals launches IPO roadshow on NYSE at $16-$18 per share
• CopperTech Metals files for IPO on NYSE under ticker CUX
• First Carolina Financial Services lists on NYSE under ticker FCBM